- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05468489
Avaliar a eficácia e segurança de HLX10 + Quimioterapia (Carboplatina-Etoposídeo) em pacientes dos EUA com ES-SCLC
Um estudo randomizado e aberto da quimioterapia HLX10 Plus (carboplatina-Etoposide) em comparação com a quimioterapia Atezolizumab Plus em pacientes dos EUA não tratados anteriormente com câncer de pulmão de pequenas células em estágio extenso (ES-SCLC)
This is a randomized, open-label study of Serplulimab plus chemotherapy (Carboplatin-Etoposide) in comparison with Atezolizumab plus chemotherapy in previously untreated US patients with ES-SCLC.
Subjects in this study will be randomized to arm A or B at 1:1 ratio as follows:
- Arm A (Serplulimab): Serplulimab + chemotherapy (carboplatin-etoposide)
- Arm B (control): Atezolizumab + chemotherapy (carboplatin-etoposide)
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
Contactos e Locais
Locais de estudo
-
-
Alabama
-
Birmingham, Alabama, Estados Unidos, 35223
- Alabama Oncology
-
-
Arizona
-
Goodyear, Arizona, Estados Unidos, 85338
- City of Hope - Phoenix
-
Tucson, Arizona, Estados Unidos, 85715
- Arizona Clinical Research Center (ACRC)
-
-
Arkansas
-
Springdale, Arkansas, Estados Unidos, 72762
- Highlands Oncology Group
-
-
California
-
Fountain Valley, California, Estados Unidos, 92708
- Compassionate Care Research Group
-
Fullerton, California, Estados Unidos, 92835
- Providence Medical Foundation
-
Glendale, California, Estados Unidos, 91204
- Los Angeles Cancer Network
-
Los Alamitos, California, Estados Unidos, 90720
- OPN - Oncology Physician Network
-
Los Angeles, California, Estados Unidos, 90034
- Kaiser Permanente Research (Southern California)
-
Sacramento, California, Estados Unidos, 95817
- UC Davis
-
-
Colorado
-
Colorado Springs, Colorado, Estados Unidos, 80920
- UCHealth Memorial Hospital North
-
Greeley, Colorado, Estados Unidos, 80631
- MD Anderson- North Colorado Medical Center
-
-
Florida
-
Brooksville, Florida, Estados Unidos, 34613
- Advanced Cancer Treatment Centers
-
Jacksonville, Florida, Estados Unidos, 32256
- Cancer Specialists North Florida
-
Miami, Florida, Estados Unidos, 33140
- Mount Sinai Comprehensive Cancer Center
-
Ocala, Florida, Estados Unidos, 34473
- Florida Cancer Affiliates- (Ocala Oncology - Main)
-
Orange City, Florida, Estados Unidos, 32763
- Mid Florida Hematology and Oncology Center
-
Plantation, Florida, Estados Unidos, 33322
- BRCR Global
-
Pompano Beach, Florida, Estados Unidos, 33064
- Napa Research
-
Tamarac, Florida, Estados Unidos, 33321
- Advanced Research
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96814
- Straub Benioff Medical Center
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60099
- City of Hope- Chicago
-
Decatur, Illinois, Estados Unidos, 62526
- Cancer Center of Decatur
-
Tinley Park, Illinois, Estados Unidos, 60487
- Accellacare of Duly
-
-
Indiana
-
Dyer, Indiana, Estados Unidos, 46311
- Northwest Cancer Centers
-
-
Kansas
-
Wichita, Kansas, Estados Unidos, 67214
- Cancer Center of Kansas
-
-
Kentucky
-
Lexington, Kentucky, Estados Unidos, 40503
- Baptist Health Lexington
-
Pikeville, Kentucky, Estados Unidos, 41501
- Pikeville Hospital
-
-
Louisiana
-
Alexandria, Louisiana, Estados Unidos, 71301
- CHRISTUS St. Frances Cabrini Cancer Center
-
Hammond, Louisiana, Estados Unidos, 70433
- Pontchartrain Cancer Center
-
-
Michigan
-
Southfield, Michigan, Estados Unidos, 48075
- Henry Ford Health Providence Southfield Hospital
-
-
Minnesota
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Health Partners Cancer Center at Regions Hospital
-
-
Mississippi
-
Hattiesburg, Mississippi, Estados Unidos, 39401
- Hattiesburg Clinic Hematology/Oncology
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64132
- MidAmerica Division Inc., c/o Research Medical Center
-
Osage Beach, Missouri, Estados Unidos, 65065
- Lake Regional
-
-
Montana
-
Billings, Montana, Estados Unidos, 59102
- St. Vincent Frontier Cancer Center
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68106
- University of Nebraska Medical Center
-
-
Nevada
-
Reno, Nevada, Estados Unidos, 89502
- Renown Health
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Dartmouth Hitchcock Medical Center
-
-
New Jersey
-
Freehold, New Jersey, Estados Unidos, 03756
- Regional Cancer Care Associates LLC RCCA
-
Neptune City, New Jersey, Estados Unidos, 07753
- Jersey Shore University Medical Center
-
-
New York
-
Elmhurst, New York, Estados Unidos, 11373
- Elmhurst (BRANY site)
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health
-
Stony Brook, New York, Estados Unidos, 11794
- Stony Brook Cancer Center
-
Williamsville, New York, Estados Unidos, 14221
- Great Lakes Cancer Care (Kaleida Health)
-
-
Ohio
-
Akron, Ohio, Estados Unidos, 44304
- Summa Health
-
Canton, Ohio, Estados Unidos, 44708
- Cleveland Clinic Mercy Hospital
-
Canton, Ohio, Estados Unidos, 44710
- Aultman Cancer Center
-
Cleveland, Ohio, Estados Unidos, 44106
- University Hospitals Cleveland Medical Center
-
Massillon, Ohio, Estados Unidos, 44646
- Tricounty Hematology and Oncology Associates
-
-
Pennsylvania
-
Wynnewood, Pennsylvania, Estados Unidos, 19096
- Lankenau Medical Center
-
-
Rhode Island
-
Providence, Rhode Island, Estados Unidos, 02908
- CharterCARE (Roger Williams)
-
-
Texas
-
Corpus Christi, Texas, Estados Unidos, 78404
- CHRISTUS Institute for Innovation & Advanced Clinical Care
-
Edinburg, Texas, Estados Unidos, 78539
- DHR Research
-
Houston, Texas, Estados Unidos, 77090
- Millennium Research and Clinical Development
-
Kingwood, Texas, Estados Unidos, 77339
- Lumi Research
-
Lubbock, Texas, Estados Unidos, 79410
- Joe Arrington Cancer Research and Treatment Center
-
Tyler, Texas, Estados Unidos, 75701
- The University of Texas Health Science Center at Tyler/HOPE Cancer Center
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Utah Cancer Specialists
-
Salt Lake City, Utah, Estados Unidos, 84112
- Huntsman Cancer Institute
-
-
Washington
-
Olympia, Washington, Estados Unidos, 98502
- American Oncology Network Vista Oncology Division
-
Tacoma, Washington, Estados Unidos, 98405
- Northwest Medical Specialties, PLLC
-
-
West Virginia
-
Morgantown, West Virginia, Estados Unidos, 26505
- West Virginia University Cancer Institute
-
-
Wisconsin
-
Madison, Wisconsin, Estados Unidos, 53792
- University of Wisconsin Carbone Cancer Center
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Froedtert Hospital- Medical College of Wisconsin
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
Voluntary participation in clinical studies.
Male or female aged ≥ 18 years at the time of signing the ICF.
Histologically or cytologically diagnosed with ES-SCLC (according to the Veterans Administration Lung Study Group staging system).
No prior systemic therapy for ES-SCLC.
Patients who have received chemoradiotherapy for previous limited stage SCLC must be treated with curative intent and have a treatment-free interval of at least 6 months from the last course of chemotherapy, radiotherapy, or chemoradiotherapy to the diagnosis of extensive stage SCLC.
At least one measurable lesion as assessed according to RECIST 1.1 within 4 weeks prior to randomization.
Every effort should be made to provide tumor tissues for the determination of PD-L1 expression.
Prior antineoplastic therapy including Chinese medicine therapy, which has been approved as antineoplastic therapy by NMPA or its instruction has antineoplastic therapy effect, must have been ≥ 2 weeks from the first dose in this study with treatment-related AEs resolved to NCI-CTCAE Grade ≤ 1 (except for Grade 2 alopecia).
An ECOG PS score of 0 or 1.
An expected survival ≥ 12 weeks.
Subjects with prior denosumab use that can and agree to switch to bisphosphonate therapy for bone metastases starting prior to randomization and throughout treatment.
Normal major organ functions.
Female patients must meet one of the following conditions: Menopause, Surgically sterilized or of child-bearing potential, must meet the following: negative serum pregnancy test within 7 days prior to randomization and agree to use birth control methods with an annual failure rate <1% or maintain abstinence. Must not be breast-feeding.
Male patients must: agree to abstinence or take contraception measures as follows: male patients with a pregnant partner or a partner of childbearing potential must remain abstinent or use a condom or had vasectomy to prevent embryonic exposure during study treatment and for at least 6 months after the last dose of study drug. Periodic abstinence and external ejaculation are ineligible methods of contraception.
Exclusion Criteria:
Histologically or cytologically confirmed mixed SCLC.
Other active malignancies within 5 years or at the same time. Localized tumors that have been cured, such as basal cell carcinoma, squamous-cell skin cancer, superficial bladder cancer, prostate carcinoma in situ, cervical cancer in situ and breast cancer in situ are acceptable.
Patients who are preparing for or have received an organ or bone marrow transplant.
Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent drainage procedures (once monthly or more frequently). Patients with indwelling catheters are allowed regardless of drainage frequency.
Patients with known or documented active CNS metastases and/or carcinomatous meningitis at screening. However, the following subjects are allowed to be enrolled: 1) Subjects with asymptomatic brain metastases may be included but are required to receive regular brain imaging as a site of lesion. 2) Subjects with treated brain metastases which have been stable for at least 2 weeks, with no evidence of new or enlarging brain metastases, and with discontinued steroids 3 days prior to study drug administration.
Subjects with spinal cord compression that has not been treated with surgery and/or radiotherapy.
Patients with myocardial infarction within half a year before the first dose of the study drug, poorly controlled arrhythmia.
Class III to IV cardiac insufficiency according to NYHA classification.
Subject has uncontrolled or symptomatic hypercalcemia.
Subject with peripheral neuropathy ≥ Grade 2 by CTCAE.
Human immunodeficiency virus (HIV) infection, positive test for HIV antibody.
Active or latent pulmonary tuberculosis.
Subjects with previous and concurrent interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis and severe impaired pulmonary function that may interfere with the detection and management of suspected drug-related pulmonary toxicity, as judged by the investigator.
Hepatitis B or Hepatitis C or Hepatitis B and C co-infection.
Known active or suspected autoimmune diseases. Subjects in a stable state with no need for systemic immunosuppressant therapy are allowed to enroll.
Have received treatment with live vaccines within 28 days prior to the first administration. Subjects may receive inactivated viral vaccines for seasonal influenza but may not receive live attenuated influenza vaccines via intranasal route.
Subjects requiring treatment with systemic corticosteroids or other immunosuppressive drugs within 14 days prior to the first dose or during the study. However, in the absence of active autoimmune disease, subjects are allowed to use topical or inhaled steroids and adrenal hormone replacement therapy at doses equivalent to ≤ 10 mg/day of prednisone efficacy.
With any active infection requiring systemic anti-infective treatment at the time of first dose of study treatment.
Major surgery within 28 days prior to the first dose of the study drug, defined as: surgeries requiring at least 3 weeks of recovery to be able to receive treatment in this study.
Radical radiation therapy within 3 months prior to study medications. Note: Palliative radiotherapy to bone or palliative radiotherapy to superficial lesions is allowed according to local standards 14 days prior to the first dose. Radiotherapy covering more than 30% of the bone marrow area within 28 days prior to the first dose is not allowed.
The subject has previously received other antibodies/drugs against immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.
Participation in any other ongoing clinical studies, or less than 14 days from the end of the previous clinical study treatment to the start of this trial.
Known history of severe allergy to any monoclonal antibody.
Known hypersensitivity to carboplatin or etoposide.
Pregnant or lactating females.
Active use of psychotropics abuse or drug abuse.
In the judgment of the investigator, the subject has any other factors that may lead to a premature discontinuation.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Serplulimab + chemotherapy
Serplulimab + chemotherapy (carboplatin-etoposide) |
Drug: Serplulimab is an innovative monoclonal antibody targeting PD-1,developed by Shanghai Henlius Biotech, Inc. Drug: carboplatin and etoposide chemotherapeutics |
|
Comparador Ativo: Atezolizumab + chemotherapy
Atezolizumab + chemotherapy (carboplatin-etoposide) |
Drug: Atezolizumab is a monoclonal antibody targeting PD-L1,developed by Roche Pharma AG. Drug: carboplatin and etoposide chemotherapeutics |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
OS
Prazo: A period from randomization through death regardless of causality (approximately up to 24 months).
|
Overall assessment |
A period from randomization through death regardless of causality (approximately up to 24 months).
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Objective response rate (ORR)
Prazo: approximately up to 14 months
|
Objective response rate (ORR) (assessed by independent radiology review committee [IRRC] and the investigator based on Response Evaluation Criteria in Solid Tumors [RECIST] 1.1) |
approximately up to 14 months
|
|
Progression-free survival (PFS)
Prazo: approximately up to 24 months
|
Progression-free survival (PFS) (assessed by IRRC and the investigator based on RECIST 1.1) |
approximately up to 24 months
|
|
PFS2
Prazo: Approximately up to 24 months
|
PFS2 (assessed by the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Duration of response (DOR)
Prazo: Approximately up to 24 months
|
Duration of response (DOR) (assessed by IRRC and the investigator based on RECIST 1.1) |
Approximately up to 24 months
|
|
Adverse events
Prazo: approximately up to 24 months
|
Number of Participants With Abnormal Laboratory Values and/or Adverse Events That Are Related to Treatment. |
approximately up to 24 months
|
|
Observed concentration of HLX10 in serum
Prazo: Approximately up to 24 months
|
Observed concentration of HLX10 in serum |
Approximately up to 24 months
|
|
Estimated PK exposure of HLX10 in serum from population pharmacokinetic analysis, expressed as mg·h/L
Prazo: Approximately up to 24 months
|
The PK data obtained in this study will be pooled with other data from HLX10 (Serplulimab) clinical trials for further population pharmacokinetic analyses. The differences in PK exposure between American population and the obtained populations (Asian and non-Asian) will be compared through model simulation. |
Approximately up to 24 months
|
|
HLX10 anti-drug antibody (ADA)
Prazo: Approximately up to 24 months
|
HLX10 anti-drug antibody (ADA) |
Approximately up to 24 months
|
|
Neutralizing antibody (NAb)
Prazo: Approximately up to 24 months
|
Neutralizing antibody (NAb) positive rate |
Approximately up to 24 months
|
|
Quality of life assessment
Prazo: Approximately up to 24 months
|
Lung cancer Quality of life assessment |
Approximately up to 24 months
|
Outras medidas de resultado
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Exploratory Endpoint
Prazo: Approximately up to 24 months
|
Potential prognostic and predictive biomarkers, including PD-L1 expression in tumor tissue and SCLC-related blood biomarker |
Approximately up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- ASTRIDE (HLX10-005-SCLC301-E)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .